《盈利預喜》維亞生物(01873.HK)料去年扭虧轉賺不少於3億人幣
維亞生物(01873.HK)發盈喜,預計2021年全年收益將按年增加超過1.8倍至約20億元人民幣(下同),預期年內錄得淨利潤不少於3億元,而2020年同期則錄得淨虧損約3.8億元。
集團預期,預期於2021年全年錄得的歸屬於公司權益股東的淨利潤不少於2.8億元,而2020年度則錄得的歸屬於公司權益股東的淨虧損約3.9億元,預計年內經調整非國際財務報告準則淨利潤不低於3.5億元,按年上 漲不少於38%,主要是因為藥物發現服務的收益大幅增加、業務範圍從前端藥物發現擴展至小分子CDMO業務,形成了藥物研究、開發和生產的一體化平台,且已被按公平值列入損益之金融資產之公平值收益較截至2020年之減幅所抵銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.